Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbsp
    Powder for the preparation of solution for intravenous and intramuscular injection.

    Composition:Cefoperazone sodium salt (in terms of cefoperazone) 250 mg, 500 mg, 1.0 g
    Sulbactam sodium salt (in terms of sulbactam) 250 mg, 500 mg, 1.0 g
    Description:The powder is white or almost white.
    Pharmacotherapeutic group:Antibiotic-cephalosporin + beta-lactamase inhibitor.
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:Pacoceph - a combined antibacterial preparation of a wide spectrum of action.

    Cefoperazone - a semi-synthetic antibiotic of the third generation of the cephalosporin series intended only for parenteral use. It is bactericidal, has a wide spectrum of action; It is highly active against aerobic and anaerobic Gram-positive and Gram-negative microorganisms. The mechanism of action is the inhibition of the biosynthesis of the mucopeptide of the cell wall.

    Sulbaktam - derivative of the main nucleus of penicillin. It is an irreversible inhibitor of beta-lactamases, which are released by microorganisms resistant to beta-lactam antibiotics; prevents the destruction of penicillins and cephalosporins under the action of beta-lactamases of resistant microorganisms; binding to penicillin-binding proteins, shows a synergism with simultaneous application with penicillins and cephalosporins.Sulbactam does not have clinically significant antibacterial activity (except for Neisseriaceae and Acinetobacter spp.). Sulbactam interacts with some penicillin-binding proteins, so cefoperazone+ [sulbactam] often has a more pronounced effect on sensitive strains than one cefoperazone. The combination of cefoperazone + [sulbactam] is active against all microorganisms sensitive to cefoperazone and acts synergistically (reduces the minimum inhibitory concentration (MIC) of the combination up to 4 times compared to cefoperazone) against microorganisms: Haemophilus influenzae, Bacteroides spp., Staphylococcus spp., Acinetobacter calcoaceticus, Enterobacter aerogenes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacter freundii, Enterobacter cloacae, Citrobacter diversus.

    Cefoperazone + [sulbactam] is active in vitro for a wide range of clinically relevant microorganisms:

    - Gram-positive microorganisms

    Staphylococcus aureus (producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic group streptococcus A), Streptococcus agalactiae (beta-hemolytic streptococcus group B), most other strains of beta-hemolytic streptococci, many strains Enterococcus faecalis.

    - Gram-negative microorganisms

    Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia spp., Serratia spp. (including Serratia marcescens), Salmonella spp. and Shigella spp., Pseudomonas aeruginosa and some others Pseudomonas spp., Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica.

    - Anaerobic microorganisms

    Gram-negative sticks (including Bacteroides fragilis, others Bacteroides spp. and Fusobacterium spp.).

    Gram-positive and gram-negative cocci (Including Peptococcus spp., Peptostreptococcus spp. and Veillonella spp.).

    Gram-positive sticks (including Clostridium spp., Eubacterium spp. and Lactobacillus spp.).

    Pharmacokinetics:

    Suction and distribution: maximum concentration (СmOh) in the serum of cefoperazone and sulbactam after intravenous administration of cefoperazone + [sulbactam] at a dose of 2 g (1 g of cefoperazone, 1 g of sulbactam) is achieved within 5 minutes and averages 237 μg / ml for cefoperazone and 130 μg / ml for sulbactam . This reflects a higher volume of sulbactam distribution (Vd = 18-28 L) compared with that of cefoperazone (Vd = 10-11 L).

    Cefoperazone and sulbactam are distributed well in various tissues and body fluids, including ascitic fluid, cerebrospinal fluid (in patients with inflammation of the meninges), urine, saliva, tonsils, skin, fallopian tubes, ovaries, uterus, lungs, bones, bile, gall bladder, appendix. The drug penetrates the placental barrier.

    Cefoperazone by 70-90%, sulbactam by 38% reversibly bind to plasma proteins. Metabolism and excretion: half-life (T1/2) of sulbactam averages about 1 hour, T1 / 2 of cefoperazone - 1.7 hours. Serum concentration is proportional to the administered dose.

    Approximately 84% of the dose of sulbactam and 25% of the dose of cefoperazone are excreted by the kidneys. The rest of cefoperazone is excreted mainly with bile.

    With repeated application of significant changes in the pharmacokinetic parameters of both components of the drug was not noted. With the introduction of the drug every 8-12 hours no cumulation was observed.

    Pharmacokinetics in special clinical cases.

    When a violation of liver function

    Cefoperazone is actively excreted with bile. The half-life of cefoperazone is usually prolonged, and the excretion of the drug by the kidneys is increased in patients with liver disease and / or biliary tract obstruction. Even with severe liver dysfunction in bile, the therapeutic concentration of cefoperazone is reached, and the elimination half-life increases only 2-4 times.

    In case of impaired renal function

    In patients with varying degrees of impaired renal function, cefoperazone+ [sulbactam], a high correlation was found between the total clearance of sulbactam from the body and the estimated clearance of creatinine. In patients with terminal renal failure, a significant increase in T1 / 2 of sulbactam was found (an average of 6.9 and 9.7 hours in various studies). Hemodialysis caused significant changes in T1 / 2, the overall clearance and the volume of distribution of sulbactam.

    In the elderly

    The pharmacokinetics of cefoperazone + [sulbactam] has been studied in elderly people with renal insufficiency and impaired liver function. In comparison with healthy volunteers, an increase in the duration of T1 / 2, a decrease in clearance and an increase in the distribution of both sulbactam and cefoperazone were found. The pharmacokinetics of sulbactam correlated with the degree of impaired renal function, and the pharmacokinetics of cefoperazone - with a degree of impaired hepatic function.

    Children

    In studies in children, there were no significant changes in the pharmacokinetic parameters of the components of cefoperazone + [sulbactam] compared with those in adults. The average T1 / 2 sulbactam in children was 0.9-1.4 h, cefoperazone 1.4-1.8 h.

    Indications:
    Infectious-inflammatory diseases caused by microorganisms sensitive to cefoperazone / sulbactam:

    - infections of the upper and lower respiratory tract (pharyngitis, tonsillitis, bronchitis, pneumonia, bronchopneumonia, pleural empyema, lung abscess);

    - infection of LOP-organs (sinusitis, otitis);

    - infection of the upper and lower parts of the urinary tract (pyelonephritis, cystitis);

    - intra-abdominal infections (peritonitis, cholecystitis, cholangitis, liver abscesses);

    - sepsis;

    - meningitis;

    - infections of the skin and soft tissues (furunculosis, abscess, pyoderma, lymphadenitis, lymphangitis);

    - infection of bones and joints (osteomyelitis);

    - inflammatory diseases of the pelvic organs (endometritis, gonorrhea);

    Prevention of infectious complications after abdominal, gynecological and orthopedic operations, in cardiovascular surgery.
    Contraindications:Hypersensitivity to sulbactam, cefoperazone, penicillins and other beta-lactam antibiotics.
    Carefully:Severe violations of kidney and liver function, colitis (including in history), children's age of up to 3 months.
    Pregnancy and lactation:The use of the drug during pregnancy is possible only in cases where the intended benefit to the mother exceeds the potential risk to the fetus.If you need to use the drug during lactation, you should decide whether to stop breastfeeding.
    Dosing and Administration:

    Intravenous (struino and drip) and intramuscularly.

    The dose of cefoperazone + [sulbactam] depends on the severity of the disease, type of infection, body condition, age, body weight and kidney function in the patient.

    Application in adults

    In adults cefoperazone+ [sulbactam] is recommended for use in the following daily doses:

    Ratio cefoperazone+ [sulbactam] sulbactam dose (g) cefoperazone dose (g)

    dose (g)

    1:1 2,0 - 4,0 1,0-2,0 1,0-2,0

    The daily dose should be divided into equal parts and administered every 12 hours. In severe and refractory infections, the daily dose of cefoperazone + [sulbactam] can be increased to 8 g with a 1: 1 ratio of the major components (ie 4 g of cefoperazone). If you need more than 8 g (with a 1: 1 ratio of the main components), an increase in the dose is achieved by the additional administration of cefoperazone. The dose should be divided into equal parts and administered every 12 hours. The recommended maximum daily dose of sulbactam is 4 g.

    Application for renal dysfunction

    In patients with creatinine clearance of 15-30 ml / min, the maximum dose of sulbactam is 1 g every 12 hours (maximum daily dose of sulbactam 2 g), and in patients with creatinine clearance less than 15 ml / min the maximum dose of sulbactam is 500 mg every 12 hours the maximum daily dose of sulbactam 1 g). In severe infections, additional administration of cefoperazone may be required.

    The pharmacokinetics of sulbactam significantly changes during hemodialysis. The half-life of cefoperazone from the blood plasma is somewhat reduced during hemodialysis. Therefore, the administration of the drug should be planned after dialysis.

    Application for violations of liver function

    If regular monitoring of serum concentration of cefoperazone is not performed, the maximum daily dose should not exceed 2 g (see section "Special instructions").

    Use in children

    Children cefoperazone+ [sulbactam] is recommended for use in the following daily doses:

    Ratio cefoperazone+ [sulbactam] sulbactam cefoperazone

    dose (mg / kg / day) dose (mg / kg / day) dose (mg / kg / day)

    1:1 40-80 20-40 20-40

    The dose should be divided into equal parts and administered every 6-12 hours.

    In severe and refractory infections, the daily dose can be increased to 160 mg / kg / day with a 1: 1 ratio of the major components. The daily dose is divided into 2-4 equal parts. If you need more than 80 mg / kg / day, calculated from the activity of cefoperazone, an increase in dose is achieved through the additional administration of cefoperazone.

    Neonatal application

    In newborns be administered every 12 hours. The maximum daily dose of sulbactam in children should not exceed 80 mg / kg / day during the first week of life of the drug.

    Method of preparing solutions for parenteral use

    Breeding:







    Maximum

    Total dose

    Equivalent doses

    Size

    ultimate

    (d)

    cefoperazone + [sulbactam]

    solvent, ml

    concentration,




    mg / ml

    0,5

    0,25 + 0,25

    1,7

    125+125

    1,0

    0,5 + 0,5

    3,4

    125 + 125

    2,0

    1,0+1,0

    6,7

    125 + 125

    Intramuscular administration (in / m):

    Sterile water for injection is used for dissolution (see table). If the drug is administered with a concentration of cefoperazone exceeding 250 mg / ml, it is recommended to prepare the solution using a lidocaine solution. Dilution is carried out in 2 stages - in a bottle containing 0.5 g of the drug, add 0.65 ml of sterile water for injection (in a vial containing 1 g - 1.3 ml,containing 2 g - 2.6 ml), shaken until complete dissolution, and then 0.2 ml of a 2% solution of lidocaine (in a vial containing 1 g of the drug - 0.4 ml, into a vial containing 2 g - 0.8 ml). The final solution will contain in 1 ml of a 0.5% solution of lidocaine about 250 mg of cefoperazone and about 250 mg of sulbactam.

    Intravenous (iv):

    For intravenous administration, the contents of the vial are dissolved in an adequate volume (see table) 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution, 5% dextrose solution in 0.9% sodium chloride solution or sterile water for injections and injected for 3 minutes.

    For intravenous infusion introduction, dissolve, as mentioned above, then dilute to 20-100 ml with the same solvent and injected for 15-60 minutes.

    Preparation of the solution using Ringer's solution of lactate. Since Ringer's lactate solution is not suitable for initial dilution, the solution is prepared in two steps: first use sterile water for injection (see table) and then dilute the resulting solution with Ringer's lactate solution to a concentration of 5 mg / ml of sulbactam. Infusion is carried out for 15-60 minutes.

    Side effects:

    From the cardiovascular system: lowering of blood pressure.

    From the digestive system: diarrhea, nausea, vomiting, pseudomembranous colitis.

    Allergic reactions: maculopapular rash, hives, itching, Stevens-Johnson syndrome, anaphylactic shock.

    On the part of the hematopoiesis system: bleeding (vitamin K deficiency), a decrease in the number of neutrophils. With long-term treatment, reversible neutropenia, a decrease in hemoglobin and hematocrit, transient eosinophilia, thrombocytopenia, leukopenia, hypoprothrombinemia develops.

    Local reactions: sometimes after intramuscular injection, there is transient pain and burning at the injection site. With intravenous administration of the drug, phlebitis may develop at the site of administration.

    Llaboratory indicators: hyperkreatininemia, transient increase in the activity of "liver" transaminases, alkaline phosphatase, hyperbilirubinemia, hematuria, false-positive Coombs test. When using a solution of Benedict or Felling, a false positive reaction to glucose in the urine can be observed.

    Other: headache, fever, chills, vasculitis.

    Overdose:
    Symptoms: neurological disorders, including convulsions.

    Treatment: symptomatic, hemodialysis is effective, especially in patients with impaired renal function.
    Interaction:
    Solutions cefoperazona + [sulbactam] and aminoglycosides should not be mixed, given the pharmaceutical incompatibility between them. If combined therapy is used, the two drugs are administered by successive infusions using separate secondary catheters, and the primary catheter is washed between doses of the drugs. Intervals between administration during the day should be as large as possible. In the process of treatment, it is necessary to monitor kidney function. When ethanol is used during treatment with cefoperazone and for up to 5 days after its administration, development of disulfiram-like effects, characterized by "hot flashes", sweating, headache and tachycardia, is possible.
    Patients who need artificial feeding (inside or parenteral) should avoid using solutions containing ethanol.
    The drug is incompatible with Ringer's lactate solution, 2% lidocaine solution (initial use of water for injection leads to the formation of a compatible mixture).Compatible with water for injection, 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution, 5% dextrose solution in 0.9% sodium chloride solution.
    Special instructions:
    Considering the wide spectrum of activity, it is possible to conduct adequate monotherapy. Patients receiving beta-lactam antibiotics, such as cephalosporins, have reported cases of severe reactions of hypersensitivity (anaphylactic).
    The risk of hypersensitivity reactions, including those leading to death, is higher in patients who have a history of hypersensitivity reactions to many allergens. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy.
    Serious anaphylactic reactions require urgent epinephrine. Intravenously injected glucocorticosteroids and provide airway patency, including intubation.
    Dose changes may be required in cases of severe obstruction of the biliary tract, severe liver disease, and renal dysfunction associated with any of these conditions.
    In patients with impaired liver function and concomitant renal dysfunction, monitoring the serum concentration of cefoperazone and correcting its dose should be necessary. If regular monitoring of serum concentration of cefoperazone in such cases is not carried out, then its daily dose should not exceed 2 g.
    When using a solution of Benedict or Feling, a false-positive reaction to glucose in the urine, false-positive Coombs test can be observed. With the simultaneous use of aminoglycosides, kidney function should be monitored.
    With prolonged use of the drug, a violation of normal intestinal microflora is possible, which can lead to the growth of Clostridium difficile and cause the development of pseudomembranous colitis. In this case, it is necessary to cancel the drug, the purpose of a specific treatment. The use of drugs that inhibit the intestinal peristalsis is contraindicated.
    In the treatment of cefoperazonom in rare cases, vitamin K deficiency developed. Patients receiving malnutrition, suffering from malabsorption (for example, in cystic fibrosis) and those who are long-term on intravenous artificial feeding may be classified as a risk group.In such cases, as well as in patients receiving anticoagulants, it is necessary to monitor prothrombin time and, in the presence of indications, prescribe vitamin K.
    With prolonged treatment, excessive growth of insensitive microorganisms can be observed. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys, liver and hematopoiesis system, especially in newborns, especially premature babies, and young children.
    Effect on the ability to drive transp. cf. and fur:
    During treatment with a combination of cefoperazone+ [sulbactam] should refrain from driving vehicles and performing work that requires increased attention and speed of psychomotor reactions.

    Form release / dosage:
    Powder for the preparation of solution for intravenous and intramuscular injection 250 mg + 250 mg, 500 mg + 500 mg, 1 g + 1 g.


    Packaging:For 500 mg (250 mg + 250 mg), 1 g (500 mg + 500 mg) or 2 g (1 g + 1 g), based on the amount of active substances in colorless transparent glass bottles, closed with rubber stoppers, crimped aluminum caps with protective plastic covers for the first opening. Each label is labeled.Each bottle, along with instructions for medical use, is placed in a cardboard box.
    Storage conditions:Store in a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001495
    Date of registration:10.02.2012 / 04.07.2016
    Expiration Date:10.02.2017
    Date of cancellation:2017-02-10
    The owner of the registration certificate:ELFA NPC, CJSC ELFA NPC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp25.10.2015
    Illustrated instructions
      Instructions
      Up